GeneDx Holdings Corp. (WGS)

Market Cap	2.13B
Revenue (ttm)	267.23M
Net Income (ttm)	-83.50M
Shares Out	27.47M
EPS (ttm)	-3.16
PE Ratio	n/a
Forward PE	192.30
Dividend	n/a
Ex-Dividend Date	n/a

Volume	655,943
Open	72.35
Previous Close	75.30
Day's Range	72.27 - 78.75
52-Week Range	2.47 - 89.11
Beta	2.10
Analysts	Strong Buy
Price Target	67.00 (-13.44%)
Earnings Date	Feb 18, 2025

About WGS

GeneDx Holdings Corp., a genomics company, provides personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery. The company accelerate the use of genomics and leverage clinical data to enable precision medicine as the standard of care. It utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process DNA-containing samples, analyzes information about patient-specific genetic variation, and generates test reports for clinicians and their patient...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 2017
• Employees: 1,000
• Stock Exchange: NASDAQ
• Ticker Symbol: WGS
• Website: https://www.genedx.com

Financial Performance

In 2023, GeneDx Holdings's revenue was $202.57 million, a decrease of -13.69% compared to the previous year's $234.69 million. Losses were -$175.77 million, -67.98% less than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for WGS stock is "Strong Buy." The 12-month stock price forecast is $67.0, which is a decrease of -13.44% from the latest price.

Price Target

$67.0

(-13.44% downside)

Analyst Consensus: Strong Buy